Latest News

The primary endpoint of the trial is non-inferiority in the mean change from baseline in best-corrected visual acuity (BCVA) at 52 weeks.

The results of a multicenter controlled clinical trial showed that the device resulted in “a significant improvement in visual acuity (VA) from baseline to month 12.

P. Dee G. Stephenson, MD, FACS, shares insights on evolving LAL technology and best practices for managing the ocular surface before and after surgery.

The deal will see MeiraGTx assume development rights to ZipBio’s experimental therapies targeting the complement pathway in geographic atrophy (GA).

The 2025 program built on its evolving reputation as a multispecialty educational forum that successfully integrates ophthalmology and optometry, premium CME content, and a family-friendly format to foster professional growth without sacrificing work–life balance.

Andrew G. Lee, MD, and Drew Carey, MD, discuss how optic disc cupping after optic neuritis reflects nerve and ganglion cell thinning, not disease type, helping distinguish it from glaucoma.

Metformin, a common diabetes medication, may be associated with less development of intermediate age-related macular degeneration (AMD).

Family-friendly format empowers continuing education.

NYU Grossman’s Preeya Mehta, MD, and Jonathan S. Williams, MD, sit down with Mount Sinai’s Louis R. Pasquale, MD, to discuss long-term safety and efficacy data from a PreserFlo microshunt trial and the role of microshunts in glaucoma surgery.